The Director of the National Institute of Health (NIH) recently announced that the agency plans “new ways to support diversity, equity, and inclusion,” and will also correct policies within the agency “that may harm our workforce and our science”. The growing call to action seems clear: the pharmaceutical IP community must support equity-mindedness and conscious inclusion if they are to realize the full benefits of a diverse workforce. In this interactive session, points of discussion will include:

• Growing the awareness of the pharmaceutical IP practitioners among underrepresented racial and ethnic groups
  • Championing their representation in the pharmaceutical IP work force
  • Advocating for diverse and young attorneys appearing in the court room
• Reviewing data showing the benefits of a diverse workforce

Speakers:
Huong T. Nguyen, General Counsel, Fosun Pharma USA Inc.
Katie Nolan-Stevaux, Specialist, Assistant General Counsel, Genentech
Wanda D. French-Brown, Partner, Fox Rothschild LLP
Stacie L. Ropka, Partner, Axinn, Veltrop & Harkrider LLP
Young J. Park, Partner, Litigation Department, Paul Hastings LLP
Valencia Martin-Wallace, Deputy Commissioner for Patents, USPTO

Please note there is a cost to attend.

CLE credit available.